联合肿瘤标志物在肺癌诊断中的临床应用研究

Clinical application study of combination tumor markers in diagnose of lung cancer

目的评价神经元特异性烯醇化酶(NSE)、可溶性细胞角蛋白19片断(CYFRA21-1)、癌胚抗原(CEA)以及铁蛋白(FER)等肿瘤标志物联合检验在肺癌诊断中的临床意义。方法应用免疫发光法和电化学发光法对肺癌组和对照组患者静脉血清中标志物含量进行测定,并比较差异。结果肺癌组标志物水平明显高于对照组,两者具有显著性差异。CEA对腺癌的检出率最高,CYFRA 21-1对鳞癌的检出率最高,达到71%。通过联合CYFRA 21-1和NSE或者CEA可以使对小细胞癌的检出率达到100%,同时对鳞癌与腺癌的检出率也有较大的提高。结论CYFRA 21-1作为单项诊断指标,其检出率水平优于其他标志物,而联合肿瘤标志物检验可以大大提高检验敏感性,尤其是联合CYFRA 21-1与NSE或者CEA。

Objective It is to evaluate the clinic significance of four different type tumor markers including NSE, CYFRA 21-1, CEA and FER in diagnose of lung cancer. Methods The marker contents of vein serum in lung cancer group and control group were detected with immunoluminescence method and electrochemiluminescence method and compared. Results The marker lever in lung cancer group was obviously higher than that in control group and there was significant difference. The detection rate of CEA was the highest for adenocareinoma. The detection rate of CYFRA 21 - 1 was the highest for squa- mous cancer （71% ）. Combination method of CYFRA 21 - 1 and NSE or CEA could make the detection rate to 100% for small cell cancer, and it could elevate the detection rate for adenocarcinoma and squamous cancer. Conclusion CYFRA 21 - 1 as a lone detect index is better than the other marker. Combination method can raise the detection sensitivity, inter alia unite CYFRA 21 1 and NSE or CEA.